Solstice Oncology, Inc., 2026-03-09
An SEC Form D private-offering notice from Boston, MA, a $298,400,851 filer-stated offering target in Biotech. Filed 2026-03-09. The source filing is one click away. For companies that filed this week, open the live feed.
What this filing says
Clinical-stage Boston biotech developing HBM4003, an anti-CTLA-4 heavy-chain-only antibody licensed from Harbour BioMed, for melanoma, colorectal cancer and other solid tumors.
This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.
Other Form D filings from the same week
each with its own page and its own EDGAR source- Aevius Labs, Inc., 2026-03-11, $2M, Boston, MA
- Slate Medicines, Inc., 2026-03-11, $130M, Boston, MA
- Nomizo Learning Labs, LLC, 2026-03-11, $1M, Westborough, MA
- ADVAC Therapeutics Inc, 2026-03-10, $5M, Columus, OH
- SwitchPoint Bio Holding, Inc., 2026-03-10, $5.3M, Wilmington, DE
- Lithios Inc., 2026-03-09, $500K, Medford, MA
The Monday digest, free
A summary of who raised money last week: the ones worth a call first, then every company that filed, by state and sector. One email, Monday mornings. No spam, unsubscribe anytime.
By subscribing you agree to our Terms and Privacy Policy.